JO3409B1 - صيغة صيدلانية في صورة أقراص ثنائية الطبقات تشتمل على مثبط لإنزيم HMG-CoA ريدكتاز وإربسارتان - Google Patents

صيغة صيدلانية في صورة أقراص ثنائية الطبقات تشتمل على مثبط لإنزيم HMG-CoA ريدكتاز وإربسارتان

Info

Publication number
JO3409B1
JO3409B1 JOP/2011/0161A JOP20110161A JO3409B1 JO 3409 B1 JO3409 B1 JO 3409B1 JO P20110161 A JOP20110161 A JO P20110161A JO 3409 B1 JO3409 B1 JO 3409B1
Authority
JO
Jordan
Prior art keywords
hmg
irbesartan
coa reductase
reductase inhibitor
pharmaceutical formulation
Prior art date
Application number
JOP/2011/0161A
Other languages
English (en)
Inventor
Kim Young-Hun
Soo Woo Jong
Ii Kim Yong
Jun Na Young
Jung Kim Min
Hyun Park Jae
Original Assignee
Hanmi Science Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=45395310&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JO3409(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Hanmi Science Co Ltd filed Critical Hanmi Science Co Ltd
Application granted granted Critical
Publication of JO3409B1 publication Critical patent/JO3409B1/ar

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1611—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Inorganic Chemistry (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steering Devices For Bicycles And Motorcycles (AREA)

Abstract

يتعلق الاختراع الحالي بصيغة صيدلانية في صورة أقراص ثنائية الطبقات تتكون من طبقة أولى تحتوي على إربسارتان أو أملاح مقبولة صيدلانيا منه وطبقة ثانية تحتوي على مثبط لإنزيم HMG-CoA ريدكتاز ومادة مضافة قاعدية، يمكنها أن تحسّن من معدل ذوبان وثبات الإربسارتان ومثبط إنزيم HMG-CoA ريدكتاز لتحسين الإتاحة الحيوية للعقار مقارنة بالصيغ المعقدة التقليدية وتقليل توليد المركبات ذات الصلة لأدنى حد، وبالتالي يمكن استخدامها بفعالية في صورة عامل علاجي ثابت وفائق لمعالجة ارتفاع ضغط الدم وارتفاع الكولسترول في الدم.
JOP/2011/0161A 2010-05-14 2011-05-12 صيغة صيدلانية في صورة أقراص ثنائية الطبقات تشتمل على مثبط لإنزيم HMG-CoA ريدكتاز وإربسارتان JO3409B1 (ar)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR20100045636 2010-05-14
KR1020100053782A KR101248804B1 (ko) 2010-05-14 2010-06-08 ＨＭＧ-ＣｏＡ 환원효소 억제제 및 이베살탄을 포함하는 이층정 약제학적 복합제제

Publications (1)

Publication Number Publication Date
JO3409B1 true JO3409B1 (ar) 2019-10-20

Family

ID=45395310

Family Applications (1)

Application Number Title Priority Date Filing Date
JOP/2011/0161A JO3409B1 (ar) 2010-05-14 2011-05-12 صيغة صيدلانية في صورة أقراص ثنائية الطبقات تشتمل على مثبط لإنزيم HMG-CoA ريدكتاز وإربسارتان

Country Status (36)

Country Link
US (1) US20130028974A1 (ar)
EP (1) EP2568972B1 (ar)
JP (1) JP5969466B2 (ar)
KR (2) KR101248804B1 (ar)
CN (1) CN103002883B (ar)
AR (1) AR081032A1 (ar)
AU (2) AU2011251085A1 (ar)
BR (1) BR112012029064B8 (ar)
CA (1) CA2798363C (ar)
CL (1) CL2012003185A1 (ar)
CO (1) CO6592025A2 (ar)
CR (1) CR20120545A (ar)
DK (1) DK2568972T3 (ar)
DO (1) DOP2012000264A (ar)
EA (1) EA023959B1 (ar)
EC (1) ECSP12012224A (ar)
ES (1) ES2645726T3 (ar)
GT (1) GT201200309A (ar)
HU (1) HUE036638T2 (ar)
IL (1) IL223012B (ar)
JO (1) JO3409B1 (ar)
MA (1) MA34313B1 (ar)
MX (1) MX342868B (ar)
MY (1) MY157307A (ar)
NI (1) NI201200170A (ar)
NZ (1) NZ604402A (ar)
PE (2) PE20130204A1 (ar)
PH (1) PH12012501965A1 (ar)
PL (1) PL2568972T3 (ar)
PT (1) PT2568972T (ar)
SG (1) SG185778A1 (ar)
SI (1) SI2568972T1 (ar)
TW (1) TW201200166A (ar)
UA (1) UA107967C2 (ar)
WO (1) WO2011142621A2 (ar)
ZA (1) ZA201209481B (ar)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103356500A (zh) * 2012-03-30 2013-10-23 肖广常 一种瑞舒伐他汀钙非诺贝特酸胆碱盐择时渗透泵控释片及其制备方法
BR102012020648A2 (pt) * 2012-08-17 2014-12-09 Hypermarcas S A Preparação farmacêutica oral sólida para a prevenção de doença cardio e cerebrovasculares e comprimido
KR20140028971A (ko) 2012-08-31 2014-03-10 한미약품 주식회사 아토바스타틴, 이르베살탄 및 탄산마그네슘을 포함하는 이층정 복합제제
KR20140030505A (ko) * 2012-08-31 2014-03-12 한미약품 주식회사 이베살탄 및 ＨＭＧ-ＣｏＡ 환원효소 억제제를 포함하는 약제학적 캡슐 복합제제
JP6068765B2 (ja) * 2013-03-14 2017-01-25 ボリュン ファーマスーティカル カンパニー リミテッド 薬学的複合製剤
KR101597004B1 (ko) * 2013-07-25 2016-02-23 씨제이헬스케어 주식회사 서방형 메트포르민과 속방형 HMG-CoA 환원효소 억제제를 포함하는 복합제제
KR20150079373A (ko) * 2013-12-30 2015-07-08 한미약품 주식회사 에제티미브 및 로수바스타틴을 포함하는 경구용 복합제제
KR101771766B1 (ko) * 2013-12-30 2017-08-28 알보젠코리아 주식회사 안지오텐신-Ⅱ 수용체 차단제 및 HMG-CoA 환원효소 저해제를 포함하는 약제학적 복합제제
CN105769793A (zh) * 2016-04-04 2016-07-20 孙爱华 一种辛伐他汀片剂及其制备方法
KR102465736B1 (ko) * 2018-12-31 2022-11-11 주식회사 보령 정제 및 이의 제조방법
KR102042626B1 (ko) * 2019-06-26 2019-11-11 한미약품 주식회사 이베살탄 및 ＨＭＧ-ＣｏＡ 환원효소 억제제를 포함하는 약제학적 캡슐 복합제제
KR102595702B1 (ko) * 2021-06-09 2023-10-30 주식회사 보령 약학적 복합 제제 및 제조 방법

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5994348A (en) * 1995-06-07 1999-11-30 Sanofi Pharmaceutical compositions containing irbesartan
SI20109A (sl) * 1998-12-16 2000-06-30 LEK, tovarna farmacevtskih in kemi�nih izdelkov, d.d. Stabilna farmacevtska formulacija
SI20848A (sl) * 2001-03-14 2002-10-31 Lek, Tovarna Farmacevtskih In Kemijskih Izdelkov, D.D. Farmacevtska formulacija, ki vsebuje atorvastatin kalcij
US6576256B2 (en) * 2001-08-28 2003-06-10 The Brigham And Women's Hospital, Inc. Treatment of patients at elevated cardiovascular risk with a combination of a cholesterol-lowering agent, an inhibitor of the renin-angiotensin system, and aspirin
JP2003073270A (ja) * 2001-08-30 2003-03-12 Nisshin Seiyaku Kk 安定性および溶出性の良好なプラバスタチンナトリウム錠
MXPA04006997A (es) * 2002-01-16 2004-12-07 Boehringer Ingelheim Pharma Comprimido farmaceutico de dos capas que comprende telmisartan y un diuretico y su preparacion.
WO2003105809A1 (en) * 2002-06-17 2003-12-24 Themis Laboratories Private Limited Multilayer tablets containing thiazolidinedione and biguanides and methods for producing them
US20050271717A1 (en) * 2003-06-12 2005-12-08 Alfred Berchielli Pharmaceutical compositions of atorvastatin
US20060078615A1 (en) * 2004-10-12 2006-04-13 Boehringer Ingelheim International Gmbh Bilayer tablet of telmisartan and simvastatin
BRPI0606883A2 (pt) * 2005-02-10 2009-12-01 Lifecycle Pharma As composição farmacêutica para administração oral, método para preparar um tablete, e, forma de dosagem sólida única
CA2625646A1 (en) * 2005-10-25 2007-05-03 Merck & Co., Inc. Combination of a dipeptidyl peptidase-4 inhibitor and an anti-hypertensive agent for the treatment of diabetes and hypertension
WO2008010008A2 (en) * 2006-07-17 2008-01-24 Wockhardt Limited Cardiovascular combinations using rennin-angiotensin inhibitors
RU2453307C2 (ru) * 2006-10-30 2012-06-20 Ханол Биофарма Ко.Лтд Комплексная фармацевтическая композиция с контролируемым высвобождением, содержащая блокаторы рецепторов ангиотензина-ii и ингибиторы гидроксиметилглутарил-кофермент а-редуктазы
WO2008068217A2 (en) * 2006-12-04 2008-06-12 Boehringer Ingelheim International Gmbh Pharmaceutical composition comprising a coated hmg-coa reductase inhibitor and an inhibitor of the renin-angiotensin system
KR20090114322A (ko) * 2008-04-29 2009-11-03 한올제약주식회사 심혈관계 질환 치료용 약제학적 제제
KR101209319B1 (ko) * 2008-04-29 2012-12-06 한올바이오파마주식회사 안지오텐신-ⅱ-수용체 차단제를 포함하는 약제학적 제제
KR20090114190A (ko) * 2008-04-29 2009-11-03 한올제약주식회사 방출성이 제어된 ＨＭＧ―ＣｏＡ 환원 효소 억제제와안지오텐신―Ⅱ―수용체 차단제의 복합 조성물
CN101590231A (zh) * 2008-05-29 2009-12-02 北京奥萨医药研究中心有限公司 血管紧张素ⅱ受体拮抗剂、他汀类降脂药和烟酸的药物组合物及其用途
CZ301299B6 (cs) * 2008-11-24 2010-01-06 Zentiva, A.S. Pevná farmaceutická kompozice s úcinnými látkami atorvastatinem a telmisartanem

Also Published As

Publication number Publication date
KR101248804B1 (ko) 2013-03-29
JP5969466B2 (ja) 2016-08-17
ECSP12012224A (es) 2012-11-30
ZA201209481B (en) 2014-02-26
IL223012A0 (en) 2013-02-03
KR20130024940A (ko) 2013-03-08
NZ604402A (en) 2015-02-27
CA2798363C (en) 2018-06-05
WO2011142621A2 (en) 2011-11-17
HUE036638T2 (hu) 2018-07-30
AU2016203739A1 (en) 2016-06-23
BR112012029064B1 (pt) 2019-10-22
EA023959B1 (ru) 2016-07-29
MX2012013175A (es) 2013-01-17
PL2568972T3 (pl) 2017-12-29
MY157307A (en) 2016-05-31
PH12012501965A1 (en) 2022-10-05
MX342868B (es) 2016-10-17
PE20130204A1 (es) 2013-03-11
NI201200170A (es) 2013-05-29
UA107967C2 (en) 2015-03-10
PT2568972T (pt) 2017-10-09
EP2568972A2 (en) 2013-03-20
HK1181685A1 (zh) 2013-11-15
AR081032A1 (es) 2012-05-30
PE20151905A1 (es) 2016-01-07
CR20120545A (es) 2012-12-06
BR112012029064B8 (pt) 2020-08-11
GT201200309A (es) 2014-03-14
BR112012029064A2 (pt) 2016-08-09
CO6592025A2 (es) 2013-01-02
CN103002883A (zh) 2013-03-27
SG185778A1 (en) 2013-01-30
KR20110126020A (ko) 2011-11-22
US20130028974A1 (en) 2013-01-31
DOP2012000264A (es) 2012-11-30
MA34313B1 (fr) 2013-06-01
CN103002883B (zh) 2015-08-26
IL223012B (en) 2019-03-31
SI2568972T1 (sl) 2017-10-30
EP2568972B1 (en) 2017-08-02
CA2798363A1 (en) 2011-11-17
JP2013526516A (ja) 2013-06-24
EA201291247A1 (ru) 2013-04-30
TW201200166A (en) 2012-01-01
AU2016203739B2 (en) 2017-11-02
ES2645726T3 (es) 2017-12-07
DK2568972T3 (da) 2017-11-06
AU2011251085A1 (en) 2013-01-10
EP2568972A4 (en) 2014-07-02
WO2011142621A3 (en) 2012-03-08
CL2012003185A1 (es) 2013-02-22

Similar Documents

Publication Publication Date Title
JO3409B1 (ar) صيغة صيدلانية في صورة أقراص ثنائية الطبقات تشتمل على مثبط لإنزيم HMG-CoA ريدكتاز وإربسارتان
MX2013014788A (es) Liberacion modificada de 4-metil-3-[[4-(3-piridinl)-2-pirimidinil] -amino]-n-[5-(4-metil-1h-imidazol-1-il)-3-(trifluoro-metil)-fenil ]-benzamida solubilizada utilizando acidos organicos.
NZ595467A (en) Sublingual pharmaceutical composition comprising a neutral oil
MX391660B (es) Formas de dosis de liberacion controlada para substancias de farmaco de alta dosis, solubles en agua e higroscopicas
MX346879B (es) Formulaciones de ketorolaco listas para su uso.
NZ601595A (en) Oral formulations and lipophilic salts of methylnaltrexone
UA116334C2 (uk) Тверді форми дозування бендамустину
CL2011003371A1 (es) Composicion farmaceutica de dosis fija, oral, solida y estable que comprende irbesartan, besilato de amlodipino y excipientes; procedimientos de preparacion; uso en el tratamiento de la hipertension.
PH12015500395A1 (en) Pharmaceutical composite capsule formulation comprising irbesartan and hmg-coa reductase inhibitor
JO3587B1 (ar) أشكال جرعات بينداموستين عن طريق الفم
NI201500027A (es) Formulación de comprimidos compuestos de dos fases que comprenden atorvastatina, irbesartan y carbonato de magnesio.
WO2012011118A3 (en) Development of a fixed dose combination dosage form containing ramipril and carvedilol
UA110792C2 (uk) Лікарська форма бендамустину для перорального застосування
TH126521A (th) สูตรทางเภสัชกรรมในรูปยาเม็ดสองชั้นที่ประกอบรวมด้วย hmg-coaรีดัคเทส อินฮิบิเตอร์ และเออร์เบซาร์แทน
TR201005911A2 (tr) Geliştirilmiş dissolüsyon profiline sahip bir ilaç formülasyonu.
TN2013000440A1 (en) Modified release of 4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]-n-5-(4-methyl-1h-imidazol-1-yl)-3-(trifluoromethyl)phenyl] benzamide solubilized using organic acids